Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

Psoriasis is an immune-mediated systemic disease with associated comorbidities, including
metabolic syndrome (MetS) which contributes substantially to premature mortality in patients …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Background: Real-life data on patients with psoriasis treated with guselkumab are few and
are needed to compare with trial-based data. We investigated the effect of clinical factors on …

Identifying patient characteristics associated with achieving treatment response to biologics
in patients with psoriasis could prevent expensive switching between biologics. The aim of …

Purpose Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe
plaque psoriasis. Materials and methods ECLIPSE, was a Phase 3, multicenter, 56-week …

Metabolic syndrome (MetS) is well recognized as a frequent comorbidity of psoriasis with
important implications for efficacy and safety of psoriasis treatment. The presence of …

Abstract Introduction Patients with psoriasis (PsO) experience impaired health-related
quality of life due to physical and psychosocial burdens. The objective of this study was to …

Background: Psoriasis is associated with cardiovascular disease and metabolic syndrome
but the effects of interleukin (IL)-17A inhibitor treatment on metabolic parameters are …